In a pilot clinical trial, administration of recombinant GLP-1 was linked to enhanced cardiac function and increased exercise tolerance in individuals with advanced HF and reduced left ventricular ejection fraction (LVEF) [56]. Here, GLP1R is linked to hydrops fetalis.